Evaxion Biotech A/S (NASDAQ:EVAX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $14.00 target price on the stock.

Evaxion Biotech A/S Stock Down 3.0 %

EVAX stock opened at $2.59 on Friday. The firm’s fifty day moving average is $2.96 and its 200 day moving average is $3.19. The firm has a market cap of $14.45 million, a PE ratio of -8.93 and a beta of -0.24. Evaxion Biotech A/S has a one year low of $2.26 and a one year high of $13.61. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. On average, research analysts forecast that Evaxion Biotech A/S will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Invst LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S at the end of the most recent quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.